Amiodarone protects diabetics and non-diabetics undergoing coronary artery bypass grafting equally

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Amiodarone protects diabetics and non-diabetics undergoing coronary artery bypass grafting equally. / Zebis, Lars R; Christensen, Thomas D; Thomsen, Henrik F; Hjortdal, Vibeke E.

In: Scandinavian Cardiovascular Journal, Vol. 42, No. 3, 06.2008, p. 173-7.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Zebis, LR, Christensen, TD, Thomsen, HF & Hjortdal, VE 2008, 'Amiodarone protects diabetics and non-diabetics undergoing coronary artery bypass grafting equally', Scandinavian Cardiovascular Journal, vol. 42, no. 3, pp. 173-7. https://doi.org/10.1080/14017430701798820

APA

Zebis, L. R., Christensen, T. D., Thomsen, H. F., & Hjortdal, V. E. (2008). Amiodarone protects diabetics and non-diabetics undergoing coronary artery bypass grafting equally. Scandinavian Cardiovascular Journal, 42(3), 173-7. https://doi.org/10.1080/14017430701798820

Vancouver

Zebis LR, Christensen TD, Thomsen HF, Hjortdal VE. Amiodarone protects diabetics and non-diabetics undergoing coronary artery bypass grafting equally. Scandinavian Cardiovascular Journal. 2008 Jun;42(3):173-7. https://doi.org/10.1080/14017430701798820

Author

Zebis, Lars R ; Christensen, Thomas D ; Thomsen, Henrik F ; Hjortdal, Vibeke E. / Amiodarone protects diabetics and non-diabetics undergoing coronary artery bypass grafting equally. In: Scandinavian Cardiovascular Journal. 2008 ; Vol. 42, No. 3. pp. 173-7.

Bibtex

@article{c18e935399124e6fa56ff8431fc96dbb,
title = "Amiodarone protects diabetics and non-diabetics undergoing coronary artery bypass grafting equally",
abstract = "OBJECTIVE: To evaluate amiodarone prophylaxis in diabetics and non-diabetics. Further to clarify whether the risk of developing atrial fibrillation is higher for diabetics than non-diabetic patients, and to evaluate whether the diabetic status has any influence on the length of in-hospital stay.DESIGN: Subgroup analysis within a randomized, controlled, double-blinded trial.RESULTS: At 30 days of follow-up atrial fibrillation was equally frequent among diabetics (22%) and non-diabetics (17%) (p =0.41). The length of in-hospital stay for diabetics was prolonged with 25% (9%; 45%). The prophylactic amiodarone was found equally efficient in diabetics and non-diabetics, as the relative risk ratios were 1.2 (0.4-5.4) and 2.0 (0.3-12.5), respectively.CONCLUSIONS: Diabetics and non-diabetics had the same effect of the amiodarone prophylaxis regime. Atrial fibrillation developed equally among diabetics and non-diabetics, but the length of stay was prolonged for diabetics.",
keywords = "Aged, Amiodarone/administration & dosage, Anti-Arrhythmia Agents/administration & dosage, Atrial Fibrillation/etiology, Coronary Artery Bypass/adverse effects, Coronary Artery Disease/drug therapy, Diabetes Mellitus/drug therapy, Double-Blind Method, Drug Administration Schedule, Female, Humans, Length of Stay, Male, Middle Aged, Risk Assessment, Time Factors, Treatment Outcome",
author = "Zebis, {Lars R} and Christensen, {Thomas D} and Thomsen, {Henrik F} and Hjortdal, {Vibeke E}",
year = "2008",
month = jun,
doi = "10.1080/14017430701798820",
language = "English",
volume = "42",
pages = "173--7",
journal = "Scandinavian Cardiovascular Journal",
issn = "1401-7458",
publisher = "Taylor & Francis",
number = "3",

}

RIS

TY - JOUR

T1 - Amiodarone protects diabetics and non-diabetics undergoing coronary artery bypass grafting equally

AU - Zebis, Lars R

AU - Christensen, Thomas D

AU - Thomsen, Henrik F

AU - Hjortdal, Vibeke E

PY - 2008/6

Y1 - 2008/6

N2 - OBJECTIVE: To evaluate amiodarone prophylaxis in diabetics and non-diabetics. Further to clarify whether the risk of developing atrial fibrillation is higher for diabetics than non-diabetic patients, and to evaluate whether the diabetic status has any influence on the length of in-hospital stay.DESIGN: Subgroup analysis within a randomized, controlled, double-blinded trial.RESULTS: At 30 days of follow-up atrial fibrillation was equally frequent among diabetics (22%) and non-diabetics (17%) (p =0.41). The length of in-hospital stay for diabetics was prolonged with 25% (9%; 45%). The prophylactic amiodarone was found equally efficient in diabetics and non-diabetics, as the relative risk ratios were 1.2 (0.4-5.4) and 2.0 (0.3-12.5), respectively.CONCLUSIONS: Diabetics and non-diabetics had the same effect of the amiodarone prophylaxis regime. Atrial fibrillation developed equally among diabetics and non-diabetics, but the length of stay was prolonged for diabetics.

AB - OBJECTIVE: To evaluate amiodarone prophylaxis in diabetics and non-diabetics. Further to clarify whether the risk of developing atrial fibrillation is higher for diabetics than non-diabetic patients, and to evaluate whether the diabetic status has any influence on the length of in-hospital stay.DESIGN: Subgroup analysis within a randomized, controlled, double-blinded trial.RESULTS: At 30 days of follow-up atrial fibrillation was equally frequent among diabetics (22%) and non-diabetics (17%) (p =0.41). The length of in-hospital stay for diabetics was prolonged with 25% (9%; 45%). The prophylactic amiodarone was found equally efficient in diabetics and non-diabetics, as the relative risk ratios were 1.2 (0.4-5.4) and 2.0 (0.3-12.5), respectively.CONCLUSIONS: Diabetics and non-diabetics had the same effect of the amiodarone prophylaxis regime. Atrial fibrillation developed equally among diabetics and non-diabetics, but the length of stay was prolonged for diabetics.

KW - Aged

KW - Amiodarone/administration & dosage

KW - Anti-Arrhythmia Agents/administration & dosage

KW - Atrial Fibrillation/etiology

KW - Coronary Artery Bypass/adverse effects

KW - Coronary Artery Disease/drug therapy

KW - Diabetes Mellitus/drug therapy

KW - Double-Blind Method

KW - Drug Administration Schedule

KW - Female

KW - Humans

KW - Length of Stay

KW - Male

KW - Middle Aged

KW - Risk Assessment

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1080/14017430701798820

DO - 10.1080/14017430701798820

M3 - Journal article

C2 - 18569948

VL - 42

SP - 173

EP - 177

JO - Scandinavian Cardiovascular Journal

JF - Scandinavian Cardiovascular Journal

SN - 1401-7458

IS - 3

ER -

ID: 242714805